Review



elacestrant  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    MedChemExpress elacestrant
    ER mutants display cancer stem cell phenotypes. CD44 hi /CD24 lo populations in ( A ) T47D ( top ) and MCF7 ( bottom ) ER (WT, Y537S, D538G) cells cultured in 2D (adherent) conditions. CD44 hi /CD24 lo populations in ( B ) T47D ( top ) and MCF7 ( bottom ) 3D (tumorsphere) conditions. Secondary tumorspheres in ( C ) T47D ( top ) and MCF7 ( bottom ) ER cells. Secondary tumorspheres in ( D ) T47D ( top ) and MCF7 ( bottom ) ER cells treated vehicle, E2 (1 nM), and/or R5020 (10 nM). Secondary tumorspheres in ( E, F ) T47D ( top ) and MCF7 ( bottom ) ER cells treated with vehicle, fulvestrant (fulv; 100 nM), 4-hydroxytamoxifen (4OHT; 100 nM), <t>elacestrant</t> (elac; 100 nM), and lasofoxifene (laso; 100 nM). Graphed data represent the mean ± SD (n = 3), unless otherwise indicated. * p < 0.05, ** p < 0.01, *** p < 0.001.
    Elacestrant, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 11 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/elacestrant/product/MedChemExpress
    Average 93 stars, based on 11 article reviews
    elacestrant - by Bioz Stars, 2026-02
    93/100 stars

    Images

    1) Product Images from "Progesterone receptors drive advanced breast cancer phenotypes including circulating tumor-and stem-like cell expansion in the context of ESR1 mutation"

    Article Title: Progesterone receptors drive advanced breast cancer phenotypes including circulating tumor-and stem-like cell expansion in the context of ESR1 mutation

    Journal: bioRxiv

    doi: 10.1101/2025.11.20.689560

    ER mutants display cancer stem cell phenotypes. CD44 hi /CD24 lo populations in ( A ) T47D ( top ) and MCF7 ( bottom ) ER (WT, Y537S, D538G) cells cultured in 2D (adherent) conditions. CD44 hi /CD24 lo populations in ( B ) T47D ( top ) and MCF7 ( bottom ) 3D (tumorsphere) conditions. Secondary tumorspheres in ( C ) T47D ( top ) and MCF7 ( bottom ) ER cells. Secondary tumorspheres in ( D ) T47D ( top ) and MCF7 ( bottom ) ER cells treated vehicle, E2 (1 nM), and/or R5020 (10 nM). Secondary tumorspheres in ( E, F ) T47D ( top ) and MCF7 ( bottom ) ER cells treated with vehicle, fulvestrant (fulv; 100 nM), 4-hydroxytamoxifen (4OHT; 100 nM), elacestrant (elac; 100 nM), and lasofoxifene (laso; 100 nM). Graphed data represent the mean ± SD (n = 3), unless otherwise indicated. * p < 0.05, ** p < 0.01, *** p < 0.001.
    Figure Legend Snippet: ER mutants display cancer stem cell phenotypes. CD44 hi /CD24 lo populations in ( A ) T47D ( top ) and MCF7 ( bottom ) ER (WT, Y537S, D538G) cells cultured in 2D (adherent) conditions. CD44 hi /CD24 lo populations in ( B ) T47D ( top ) and MCF7 ( bottom ) 3D (tumorsphere) conditions. Secondary tumorspheres in ( C ) T47D ( top ) and MCF7 ( bottom ) ER cells. Secondary tumorspheres in ( D ) T47D ( top ) and MCF7 ( bottom ) ER cells treated vehicle, E2 (1 nM), and/or R5020 (10 nM). Secondary tumorspheres in ( E, F ) T47D ( top ) and MCF7 ( bottom ) ER cells treated with vehicle, fulvestrant (fulv; 100 nM), 4-hydroxytamoxifen (4OHT; 100 nM), elacestrant (elac; 100 nM), and lasofoxifene (laso; 100 nM). Graphed data represent the mean ± SD (n = 3), unless otherwise indicated. * p < 0.05, ** p < 0.01, *** p < 0.001.

    Techniques Used: Cell Culture



    Similar Products

    elacestrant  (MedChemExpress)
    93
    MedChemExpress elacestrant
    ER mutants display cancer stem cell phenotypes. CD44 hi /CD24 lo populations in ( A ) T47D ( top ) and MCF7 ( bottom ) ER (WT, Y537S, D538G) cells cultured in 2D (adherent) conditions. CD44 hi /CD24 lo populations in ( B ) T47D ( top ) and MCF7 ( bottom ) 3D (tumorsphere) conditions. Secondary tumorspheres in ( C ) T47D ( top ) and MCF7 ( bottom ) ER cells. Secondary tumorspheres in ( D ) T47D ( top ) and MCF7 ( bottom ) ER cells treated vehicle, E2 (1 nM), and/or R5020 (10 nM). Secondary tumorspheres in ( E, F ) T47D ( top ) and MCF7 ( bottom ) ER cells treated with vehicle, fulvestrant (fulv; 100 nM), 4-hydroxytamoxifen (4OHT; 100 nM), <t>elacestrant</t> (elac; 100 nM), and lasofoxifene (laso; 100 nM). Graphed data represent the mean ± SD (n = 3), unless otherwise indicated. * p < 0.05, ** p < 0.01, *** p < 0.001.
    Elacestrant, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/elacestrant/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    elacestrant - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    rad 1901  (MedChemExpress)
    93
    MedChemExpress rad 1901
    ER mutants display cancer stem cell phenotypes. CD44 hi /CD24 lo populations in ( A ) T47D ( top ) and MCF7 ( bottom ) ER (WT, Y537S, D538G) cells cultured in 2D (adherent) conditions. CD44 hi /CD24 lo populations in ( B ) T47D ( top ) and MCF7 ( bottom ) 3D (tumorsphere) conditions. Secondary tumorspheres in ( C ) T47D ( top ) and MCF7 ( bottom ) ER cells. Secondary tumorspheres in ( D ) T47D ( top ) and MCF7 ( bottom ) ER cells treated vehicle, E2 (1 nM), and/or R5020 (10 nM). Secondary tumorspheres in ( E, F ) T47D ( top ) and MCF7 ( bottom ) ER cells treated with vehicle, fulvestrant (fulv; 100 nM), 4-hydroxytamoxifen (4OHT; 100 nM), <t>elacestrant</t> (elac; 100 nM), and lasofoxifene (laso; 100 nM). Graphed data represent the mean ± SD (n = 3), unless otherwise indicated. * p < 0.05, ** p < 0.01, *** p < 0.001.
    Rad 1901, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rad 1901/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    rad 1901 - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    19822a  (MedChemExpress)
    93
    MedChemExpress 19822a
    ER mutants display cancer stem cell phenotypes. CD44 hi /CD24 lo populations in ( A ) T47D ( top ) and MCF7 ( bottom ) ER (WT, Y537S, D538G) cells cultured in 2D (adherent) conditions. CD44 hi /CD24 lo populations in ( B ) T47D ( top ) and MCF7 ( bottom ) 3D (tumorsphere) conditions. Secondary tumorspheres in ( C ) T47D ( top ) and MCF7 ( bottom ) ER cells. Secondary tumorspheres in ( D ) T47D ( top ) and MCF7 ( bottom ) ER cells treated vehicle, E2 (1 nM), and/or R5020 (10 nM). Secondary tumorspheres in ( E, F ) T47D ( top ) and MCF7 ( bottom ) ER cells treated with vehicle, fulvestrant (fulv; 100 nM), 4-hydroxytamoxifen (4OHT; 100 nM), <t>elacestrant</t> (elac; 100 nM), and lasofoxifene (laso; 100 nM). Graphed data represent the mean ± SD (n = 3), unless otherwise indicated. * p < 0.05, ** p < 0.01, *** p < 0.001.
    19822a, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/19822a/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    19822a - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    ER mutants display cancer stem cell phenotypes. CD44 hi /CD24 lo populations in ( A ) T47D ( top ) and MCF7 ( bottom ) ER (WT, Y537S, D538G) cells cultured in 2D (adherent) conditions. CD44 hi /CD24 lo populations in ( B ) T47D ( top ) and MCF7 ( bottom ) 3D (tumorsphere) conditions. Secondary tumorspheres in ( C ) T47D ( top ) and MCF7 ( bottom ) ER cells. Secondary tumorspheres in ( D ) T47D ( top ) and MCF7 ( bottom ) ER cells treated vehicle, E2 (1 nM), and/or R5020 (10 nM). Secondary tumorspheres in ( E, F ) T47D ( top ) and MCF7 ( bottom ) ER cells treated with vehicle, fulvestrant (fulv; 100 nM), 4-hydroxytamoxifen (4OHT; 100 nM), elacestrant (elac; 100 nM), and lasofoxifene (laso; 100 nM). Graphed data represent the mean ± SD (n = 3), unless otherwise indicated. * p < 0.05, ** p < 0.01, *** p < 0.001.

    Journal: bioRxiv

    Article Title: Progesterone receptors drive advanced breast cancer phenotypes including circulating tumor-and stem-like cell expansion in the context of ESR1 mutation

    doi: 10.1101/2025.11.20.689560

    Figure Lengend Snippet: ER mutants display cancer stem cell phenotypes. CD44 hi /CD24 lo populations in ( A ) T47D ( top ) and MCF7 ( bottom ) ER (WT, Y537S, D538G) cells cultured in 2D (adherent) conditions. CD44 hi /CD24 lo populations in ( B ) T47D ( top ) and MCF7 ( bottom ) 3D (tumorsphere) conditions. Secondary tumorspheres in ( C ) T47D ( top ) and MCF7 ( bottom ) ER cells. Secondary tumorspheres in ( D ) T47D ( top ) and MCF7 ( bottom ) ER cells treated vehicle, E2 (1 nM), and/or R5020 (10 nM). Secondary tumorspheres in ( E, F ) T47D ( top ) and MCF7 ( bottom ) ER cells treated with vehicle, fulvestrant (fulv; 100 nM), 4-hydroxytamoxifen (4OHT; 100 nM), elacestrant (elac; 100 nM), and lasofoxifene (laso; 100 nM). Graphed data represent the mean ± SD (n = 3), unless otherwise indicated. * p < 0.05, ** p < 0.01, *** p < 0.001.

    Article Snippet: ErSO (David Shapiro, University of Illinois Urbana-Champaign), KIRA8 (Selleckchem), Ceapin-A7 (Selleckchem), GSK2606414 (Selleckchem), PRA-027 (Geoffrey Greene, University of Chicago), elacestrant (elac; MedChemExpress), lasofoxifene (laso; Sigma) stocks were prepared in DMSO.

    Techniques: Cell Culture